shutterstock_1569359980_sundry-photography

shutterstock_1569359980_Sundry Photography

18 May 2023Big PharmaMuireann Bolger

US govt seeks new trial in Gilead HIV drug patent case

The government lost its high stakes and unusual royalties dispute with the big pharma firm | New status report claims that the court should have allowed the jury to take four inter partes petitions into account.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Gilead and Teva prevail in $3.6bn antitrust trial

4 July 2023 Verdict confirms legality of 2014 patent settlement, dismissing allegations of anti competitive practices.

Trial set for Gilead HIV antitrust claims case

23 February 2023 Gilead, Johnson & Johnson and others will face trial in May | Class-action suit involves allegations of anticompetitive practices.

Gilead hit with antitrust suit over HIV drugs

16 January 2020 Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.

More on this story

Gilead and Teva prevail in $3.6bn antitrust trial

4 July 2023 Verdict confirms legality of 2014 patent settlement, dismissing allegations of anti competitive practices.

Trial set for Gilead HIV antitrust claims case

23 February 2023 Gilead, Johnson & Johnson and others will face trial in May | Class-action suit involves allegations of anticompetitive practices.

Gilead hit with antitrust suit over HIV drugs

16 January 2020 Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.

More on this story

Gilead and Teva prevail in $3.6bn antitrust trial

4 July 2023 Verdict confirms legality of 2014 patent settlement, dismissing allegations of anti competitive practices.

Trial set for Gilead HIV antitrust claims case

23 February 2023 Gilead, Johnson & Johnson and others will face trial in May | Class-action suit involves allegations of anticompetitive practices.

Gilead hit with antitrust suit over HIV drugs

16 January 2020 Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims